Nanze Yu, Wenyun Ting, Jinhua Xu, Wenyu Wu, Hang Wang, Jufang Zhang, Jiaming Sun, Zhiqi Hu, Sufan Wu, Xiaojun Wang
{"title":"一项多中心、随机、评估盲、无治疗对照研究：YVOIRE Y-Solution 720：一种用于中脸容积缺陷的透明质酸填充剂。","authors":"Nanze Yu, Wenyun Ting, Jinhua Xu, Wenyu Wu, Hang Wang, Jufang Zhang, Jiaming Sun, Zhiqi Hu, Sufan Wu, Xiaojun Wang","doi":"10.1007/s00266-025-05246-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Midface volume deficiency is a common aesthetic concern that can be addressed with dermal fillers. YVOIRE Y-Solution 720 (YYS720) is a hyaluronic acid (HA)-based filler designed for midface augmentation. This study aimed to evaluate the effectiveness and safety of YYS720 in improving midface volume.</p><p><strong>Methods: </strong>Asian participants with mild to severe midface volume loss were randomly assigned to receive either YYS720 injection (n = 173) or no treatment (control, n = 65). Midface volume was evaluated at 4, 14, and 26 weeks using Midface Volume Deficit Severity Rating Scale for Asian Faces (MFVDA-SRS) for both YYS720 and control groups. Additionally, for YYS720, midface volume was evaluated 52 weeks after the last injection.</p><p><strong>Results: </strong>At Week 26, the proportion of participants with ≥ 1-grade reduction on the MFVDA-SRS score was 82.0% (137/167 participants) for YYS720 and 5.1% (3/59 participants) for control with difference (95% confidence interval, CI) between the groups of 77.0% (66.8, 84.0), demonstrating the statistically significant improvement of YYS7720 in midface augmentation. At Week 52, the proportion of participants with ≥1-grade reduction on the MFVDA-SRS score was 76.2% for YYS720 group. Global Aesthetic Improvement Scale (GAIS) responder rates by participants were consistently high in YYS720 group across all time points up to Week 26. No specific safety concern was detected. Common treatment site responses included swelling, tenderness, and pain, which were generally mild and transient.</p><p><strong>Conclusions: </strong>This study supports that YVOIRE Y-Solution 720 is an effective and safe option for midface volume augmentation.</p><p><strong>Level of evidence i: </strong>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</p>","PeriodicalId":7609,"journal":{"name":"Aesthetic Plastic Surgery","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Multicenter, Randomized, Evaluator-Blind, No-Treatment Controlled Study of YVOIRE Y-Solution 720: A Volumizing Hyaluronic Acid Filler for Midface Volume Deficit.\",\"authors\":\"Nanze Yu, Wenyun Ting, Jinhua Xu, Wenyu Wu, Hang Wang, Jufang Zhang, Jiaming Sun, Zhiqi Hu, Sufan Wu, Xiaojun Wang\",\"doi\":\"10.1007/s00266-025-05246-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Midface volume deficiency is a common aesthetic concern that can be addressed with dermal fillers. YVOIRE Y-Solution 720 (YYS720) is a hyaluronic acid (HA)-based filler designed for midface augmentation. This study aimed to evaluate the effectiveness and safety of YYS720 in improving midface volume.</p><p><strong>Methods: </strong>Asian participants with mild to severe midface volume loss were randomly assigned to receive either YYS720 injection (n = 173) or no treatment (control, n = 65). Midface volume was evaluated at 4, 14, and 26 weeks using Midface Volume Deficit Severity Rating Scale for Asian Faces (MFVDA-SRS) for both YYS720 and control groups. Additionally, for YYS720, midface volume was evaluated 52 weeks after the last injection.</p><p><strong>Results: </strong>At Week 26, the proportion of participants with ≥ 1-grade reduction on the MFVDA-SRS score was 82.0% (137/167 participants) for YYS720 and 5.1% (3/59 participants) for control with difference (95% confidence interval, CI) between the groups of 77.0% (66.8, 84.0), demonstrating the statistically significant improvement of YYS7720 in midface augmentation. At Week 52, the proportion of participants with ≥1-grade reduction on the MFVDA-SRS score was 76.2% for YYS720 group. Global Aesthetic Improvement Scale (GAIS) responder rates by participants were consistently high in YYS720 group across all time points up to Week 26. No specific safety concern was detected. Common treatment site responses included swelling, tenderness, and pain, which were generally mild and transient.</p><p><strong>Conclusions: </strong>This study supports that YVOIRE Y-Solution 720 is an effective and safe option for midface volume augmentation.</p><p><strong>Level of evidence i: </strong>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</p>\",\"PeriodicalId\":7609,\"journal\":{\"name\":\"Aesthetic Plastic Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aesthetic Plastic Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00266-025-05246-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Plastic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00266-025-05246-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
A Multicenter, Randomized, Evaluator-Blind, No-Treatment Controlled Study of YVOIRE Y-Solution 720: A Volumizing Hyaluronic Acid Filler for Midface Volume Deficit.
Background: Midface volume deficiency is a common aesthetic concern that can be addressed with dermal fillers. YVOIRE Y-Solution 720 (YYS720) is a hyaluronic acid (HA)-based filler designed for midface augmentation. This study aimed to evaluate the effectiveness and safety of YYS720 in improving midface volume.
Methods: Asian participants with mild to severe midface volume loss were randomly assigned to receive either YYS720 injection (n = 173) or no treatment (control, n = 65). Midface volume was evaluated at 4, 14, and 26 weeks using Midface Volume Deficit Severity Rating Scale for Asian Faces (MFVDA-SRS) for both YYS720 and control groups. Additionally, for YYS720, midface volume was evaluated 52 weeks after the last injection.
Results: At Week 26, the proportion of participants with ≥ 1-grade reduction on the MFVDA-SRS score was 82.0% (137/167 participants) for YYS720 and 5.1% (3/59 participants) for control with difference (95% confidence interval, CI) between the groups of 77.0% (66.8, 84.0), demonstrating the statistically significant improvement of YYS7720 in midface augmentation. At Week 52, the proportion of participants with ≥1-grade reduction on the MFVDA-SRS score was 76.2% for YYS720 group. Global Aesthetic Improvement Scale (GAIS) responder rates by participants were consistently high in YYS720 group across all time points up to Week 26. No specific safety concern was detected. Common treatment site responses included swelling, tenderness, and pain, which were generally mild and transient.
Conclusions: This study supports that YVOIRE Y-Solution 720 is an effective and safe option for midface volume augmentation.
Level of evidence i: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
期刊介绍：
Aesthetic Plastic Surgery is a publication of the International Society of Aesthetic Plastic Surgery and the official journal of the European Association of Societies of Aesthetic Plastic Surgery (EASAPS), Società Italiana di Chirurgia Plastica Ricostruttiva ed Estetica (SICPRE), Vereinigung der Deutschen Aesthetisch Plastischen Chirurgen (VDAPC), the Romanian Aesthetic Surgery Society (RASS), Asociación Española de Cirugía Estética Plástica (AECEP), La Sociedad Argentina de Cirugía Plástica, Estética y Reparadora (SACPER), the Rhinoplasty Society of Europe (RSE), the Iranian Society of Plastic and Aesthetic Surgeons (ISPAS), the Singapore Association of Plastic Surgeons (SAPS), the Australasian Society of Aesthetic Plastic Surgeons (ASAPS), the Egyptian Society of Plastic and Reconstructive Surgeons (ESPRS), and the Sociedad Chilena de Cirugía Plástica, Reconstructiva y Estética (SCCP).
Aesthetic Plastic Surgery provides a forum for original articles advancing the art of aesthetic plastic surgery. Many describe surgical craftsmanship; others deal with complications in surgical procedures and methods by which to treat or avoid them. Coverage includes "second thoughts" on established techniques, which might be abandoned, modified, or improved. Also included are case histories; improvements in surgical instruments, pharmaceuticals, and operating room equipment; and discussions of problems such as the role of psychosocial factors in the doctor-patient and the patient-public interrelationships.
Aesthetic Plastic Surgery is covered in Current Contents/Clinical Medicine, SciSearch, Research Alert, Index Medicus-Medline, and Excerpta Medica/Embase.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
